Drug Profile
ML 007
Alternative Names: ML-007Latest Information Update: 09 Jan 2024
Price :
$50
*
At a glance
- Originator MapLight Therapeutics
- Class Antipsychotics
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Dyskinesias; Psychotic disorders; Schizophrenia
Most Recent Events
- 03 Jan 2024 Phase-I clinical trials in Dyskinesias (In volunteers) (PO) (prior to January 2024)
- 03 Jan 2024 Pharmacokinetics and adverse events data from a phase I trial in Dyskinesias released by MapLight Therapeutics
- 03 Jan 2024 MapLight Therapeutics completes a phase I trial in Dyskinesias (In volunteers) (PO)